In HIV-2, ipr follows i'if and ip.x and precedes t(it; it is predicted to encode a protein of 105 amino acids (5) . The VPR products of HIV-1 and HIV-2 are well conserved, with 52%, amino acid homology, only slightly less than that of GAG and POL products (16) . The i'pr gene is also found in simian immunodeficiency virus from rhesus macaques (1) but not from African green monkeys (4) . A similar sequence is also found in the visna virus genome (15) .
To analyze the function of the HIV-1 VPR product. we constructed three oligonucleotide-directed mutations (15) by using a functional proviral clone, pX (2, 12) . Oligonucleotides were synthesized and used for mutagenesis (9) to create termination codons at positions 3, 23, and 32 of the ip' gene product. The mutation at codon 3 was created by a cytosineto-thymidine transition at nucleotide position 5145 of the parental genome, resulting in a 2-amino-acid VPR product. At codon 23, a termination codon and a unique XbaI site were created by inserting a cytosine residue between posi-* Corresponding author. tions 5204 and 5205, resulting in a predicted VPR product of 22 amino acids. At codon 32, a termination codon and a unique XbaI site were created by the insertion of a cytosine residue between positions 5230 and 5231, resulting in a predicted VPR product of 31 amino acids. Another mutation was constructed by digestion at the NcoI site at position 5256 and insertion of four nucleotides with Eshe/ric/ija (oli DNA polymerase I Klenow fragment, causing a frameshift mutation after VPR residue 40, which truncates the protein and adds three amino acids. These mutants are designated pR2, pR22, pR31, and pR40, respectively. Each mutation was confirmed by nucleotide sequencing (14) .
A mutation in a functional HIV-2 proviral clone (pSE) (10; our unpublished results) was constructed by a guanosineto-thymidine transversion at position 5700, thus introducing a termination codon at VPR residue 7 and eliminating a Sacl restriction enzyme site. This clone is designated pMR7. An additional clone, designated pMRR, predicted to encode a full-length VPR product. was constructed with a change of an adenosine to a cytosine at position 5738, introducing a SinatI restriction site.
Virus production from each HIV-1 proviral clone was assessed by transfection of COS-1 or Jurkat cells and measurement of soluble p24 antigen production by enzymelinked immunosorbent assay (Du Pont Co.). No significant differences in virus production were detected in cells transfected with pX compared with those transfected with pR2. pR22, pR31, or pR40 (results not shown). Furthermore, no differences were noted in TAT production by these clones as measured by their ability to truans-activate HIV-1 long terminal repeat-directed gene expression (results not shown).
To produce virus stocks from each proviral clone, we cocultivated H9 or CEM lymphoid cells with transfected COS-1 cells. Total cellular DNA was isolated from the infected cells and analyzed by Southern blot hybridization (Fig. 1 ). These data demonstrate that there are equivalent levels of proviral DNA in each infected cell line, as shown by the similar intensity of the hybridization signals ( 2). The mutation in R40 was shown by the loss of the Ncol site (Fig. ic, lane 2 pR2 and pX generates hybridizing bands of 16.0 and 1.1 kb, whereas the EcoRI digestion products of infected-cell DNA are about 9.0 and 1.1 kb, owing to the loss of plasmid DNA sequences (Fig. lb) .
Titers of virus stocks from conditioned medium of the infected H9 cells were determined by reverse transcriptase (11) and soluble p24 antigen assays. Equivalent amounts of undiluted. 5-fold-diluted, or 25-fold-diluted virus were then used to infect Molt-3 cells (Fig. 2a) . Similar infectivity and replication rates were seen in viruses with or without an intact vpr gene, as demonstrated by a similar production of reverse transcriptase over time at each dilution. Furthermore, no alterations in cytopathogenicity were detected, as measured by cell killing (Fig. 2b) (results not shown). Similar infectivity, replication, and cytopathic effects were found with R2, R22, R31, R40, and X in H9, Molt3 and CEM cells and with R40 and X in U937, SUP TI, and peripheral blood mononuclear cells (results not shown).
The HIV-2 VPR mutant, MR7, also demonstrated similar virus production to that of SE and MRR after transfection of COS-1 cells (results not shown). Virus obtained from MR7 infected and replicated at a similar level to SE and MRR in CEM, Sup Ti, U937, and H9 cell lines (results not shown) and peripheral blood mononuclear cells (Fig. 3a) . No differences in syncytium production (data not shown) or cell killing (Fig. 3b) were noted for MR7-, SE-, and MRRinfected cells.
These data demonstrate that ipr is dispensable for HIV-1 and HIV-2 infectivity, replication, and cell killing. Although the VPR protein is synthesized in infected individuals (16 
